Newsroom Search

featured news

April 25, 2014 General

Pfizer Unsuccessful in Avoiding Off-Label Marketing False Claims Act Case

In a recent False Claims Act case involving the mental health drug Geodon, Pfizer reportedly lost its bid to have the case dismissed after unsuccessfully arguing, among other claims, that relators failed the “first-to-file” and “public disclosure” requirements contained within the language of the FCA. Specifically, the FCA precludes whistleblowers […]
April 21, 2014 General

Detroit-Area Physician Pleads Guilty to Medicare Fraud and Violations of the False Claims Act

When a physician, hospital, or pharmaceutical company engages in fraud against the U.S. government, it is not uncommon for the defendant to face additional penalties and sanctions beyond mere repayment of taxpayer dollars. For example, Medicare fraudsters may face incarceration and probation for engaging in this type of crime – […]
April 15, 2014 General

American Family Care Inc. to Pay $1.2 Million to Settle Medicaid and Medicare Fraud Claims

In its latest efforts to combat Medicare fraud, the Department of Justice recently announced a $1.2 million settlement with an Alabama-based walk-in clinic. American Family Care, Inc. has agreed to the settlement after allegations of upcoding and fraudulent invoice practices surfaced when a whistleblower filed a qui tam lawsuit against […]
April 10, 2014 General

Repeat Offender Valley Heart Consultants to Pay $3.9 Million to Settle Claims of Medicare Fraud

In a recent press release, the Department of Justice applauds the concerted efforts of the Department of Health and Human Services with the FBI in identifying and investigating allegations of billing fraud spanning nearly six years. According to allegations, Texas-based Valley Heart Consultants was engaging in the practice of performing […]
April 9, 2014 General

Arkansas Supreme Court Takes Different View of Risperdal Fraud Case

Late last year, the federal Department of Justice settled a long-running dispute with drug maker Johnson & Johnson over allegations of the off-label marketing of the anti-psychotic drug Risperdal. As is often the case, Johnson & Johnson also faced several state False Claims Act and Deceptive Trade Practices Act allegations, […]
$2.4B+
in 2025 post-trial judgments
$50B+
in Settlements & Verdicts
55+
Years of Experience With High-Profile Cases
100+
Attorneys Protecting Your Rights
20+
Years Ranked as Top Law Firm by Chambers USA
50
States in Which The Firm Has Successfully Litigated

On the Cutting Edge of the Profession

Legal Intelligencer